Clinical Trial

UK ENcorafenib and BInimetinib Real-world Study in Melanoma

Study acronym: UK-EnBiRiM
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This is a prospective longitudinal multi-centre observational study conducted in the United Kingdom, in patients with metastatic cutaneous BRAF V600 mutation-positive melanoma assigned to receive encorafenib and binimetinib. The aim of this study is to learn about how encorafenib and binimetinib perform, patients' experiences of using them, and how they might affect patient's quality of life, in the real world, when these treatments are prescribed by doctors instead of in a clinical trial. Participants will complete electronic data entry via questionnaires over a 24-month period. Site research teams will also complete electronic data entry using participants' medical records over a 24-month period.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-06; most recent amendment 2026-04-09.
Status change: Recruiting → Active, Not Recruiting 2026-04-09
Status change: Not Yet Recruiting → Recruiting 2025-07-30
Trial Details
NCT Number NCT07022457
Lead Sponsor Pierre Fabre Ltd
Collaborators: Vitaccess Ltd
Conditions Metastatic Melanoma, BRAF V600 Mutation Positive
Enrollment 50 participants
Start Date 2025-07-31
Primary Completion 2028-01-13 (estimated)
Study Completion 2028-01-13 (estimated)
Updated on ClinicalTrials.gov 2026-04-13